Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
10 novembre 2026
Herbert Smith Freehills Kramer advises joint sponsors and underwriters of Denglin Technology on its Hong Kong IPO
Global law firm Herbert Smith Freehills Kramer has advised CITIC Securities (Hong Kong) Limited, China Securities (International) Corporate Finance …
10 novembre 2026
Benchmark Litigation 2027 recognizes HSF Kramer
The 2027 edition of Benchmark Litigation has named 22 HSF Kramer partners to its annual list of litigation stars, future stars, and national …
9 novembre 2026
Herbert Smith Freehills Kramer advises Meiban Group on the acquisition of Planet Innovation
Herbert Smith Freehills Kramer has advised Meiban Group on its acquisition of Planet Innovation by way of scheme of arrangement.